Agendia
Agendia Gets CE-IVDR Certification for MammaPrint, BluePrint FFPE Breast Cancer Tests
The assays are versions of Agendia’s MammaPrint and BluePrint tests that use formalin-fixed paraffin-embedded tissue samples instead of fresh tissue.
UK's NICE Expands Tumor Profiling Recommendations for Guiding Adjuvant Chemo in Early Breast Cancer
Previously, NICE recommended EndoPredict, Prosigna, and Oncotype DX for node-negative breast cancer only, but the new guidance includes lymph node-positive disease.
In Brief This Week: Agendia, Mainz Biomed, CeGaT, Telo Genomics, Eurofins, Gencove, More
News items for the week of April 8, 2024
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
People in the News at Foundation Medicine, Personalis, Agendia, BioMérieux, Genetic Signatures
Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of June 12, 2023.
Jun 4, 2023
Jun 12, 2020
Dec 10, 2018
SABCS 2018 Features Molecular Diagnostics Research
Nov 16, 2018
Jul 25, 2018